Condition: Marginal Zone Lymphoma · Sponsor: The Lymphoma Academic Research Organisation
This is an open label, multi-center, international, randomized phase III trial to compare the efficacy of Mosunetuzumab-Lenalidomide with investigator choices exclusively in R/R MZL patients. Patients with a proven diagnosis of EMZL, SMZL or NMZL subtypes and previously treated with at least one prior systemic treatment and not more than three prior lines are eligible. Previous treatment line must include at least one systemic line with a drug targeting CD20 (monoclonal antibody at least 2 cycles) with or without chemotherapy (R-CHOP, R-Bendamustine, R-CVP, R-Chlorambucil at least 2 cycles) or targeted treatment such as Ibrutinib. The patients will be Randomized as follows: Arm A - Experimental arm: • Mosunetuzumab-Lenalidomide Arm B - Comparator arms ( Investigator Choices): * Rituximab-Lenalidomide * Rituximab-Bendamustine * Rituximab-CHOP
This description comes directly from the study's public registry record.
Christine STEPHAN · 04 72 66 38 76 · christine.stephan@lysarc.org
Always discuss trial participation with your own doctor first.
| INSTITUT JULES BORDET - Service Hématologie | Anderlecht, Belgium | Not Yet Recruiting |
| UNIVERSITE CATHOLIQUE DE LOUVAIN SAINT-LUC - Service Hématologie | Brussels, Belgium | Not Yet Recruiting |
| UNIVERSITAIR ZIEKENHUIS GENT - Service Hématologie | Ghent, Belgium | Recruiting |
| CHU UCL NAMUR - SITE GODINNE - Service Hématologie | Yvoir, Belgium | Not Yet Recruiting |
| CHU de Nancy - Brabois | Nancy, France, France | Recruiting |
| CHU d'Amiens | Amiens, France | Recruiting |
| CH d'Avignon - Hopital Henri Duffaut | Avignon, France | Recruiting |
| CH de la Côte Basque - Hôpital de Bayonne | Bayonne, France | Recruiting |
| CHRU Besançon - Hôpital Minjoz | Besançon, France | Recruiting |
| Institut Bergonié | Bordeaux, France | Recruiting |
| Chu Estaing | Clermont-Ferrand, France | Recruiting |
| CHU Henri Mondor | Créteil, France | Recruiting |
+ 36 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06006117